Italia markets open in 44 minutes

ERYTECH Pharma S.A. (0QSS.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
2,2600-0,0650 (-2,80%)
Alla chiusura: 02:36PM GMT
Schermo intero
Chiusura precedente2,3250
Aperto2,2600
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno2,2600 - 2,2600
Intervallo di 52 settimane2,2600 - 2,2600
Volume190
Media VolumeN/D
Capitalizzazione35,054M
Beta (5 anni mensile)1,74
Rapporto PE (ttm)N/D
EPS (ttm)-3,1810
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors

    ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors Prior treatment with methioninase shown to sensitize certain solid tumor types to asparaginase-based treatmentNew patent granting adding to portfolio of 310 granted patents in 16 patent families Cambridge, MA (U.S.) and Lyon (France), November 29, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therap

  • GlobeNewswire

    ERYTECH Provides Business and Financial Update for the Third Quarter of 2021

    ERYTECH Provides Business and Financial Update for the Third Quarter of 2021 Conference call and webcast on Tuesday, November 16, 2021at 8:30am EST / 2:30pm CET Progress towards seeking approval of eryaspase for the treatment of ALL patients who experienced hypersensitivity to pegylated asparaginase; Fast Track designation granted; submission of BLA intended around year-endPhase 3 trial in second-line pancreatic cancer did not meet its primary endpoint Recommended Phase 2 dose determined from Ph

  • GlobeNewswire

    ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting

    ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting Cambridge, MA (U.S.) and Lyon (France), November 15, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the acceptance of an abstract with the results of its expanded access program (EAP) evaluating eryaspase in acute lymphoblastic leuke